Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

Abstract Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-particle emitter 211At-labeled to the anti-PSCA A11 minibo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EJNMMI Research
Auteurs principaux: Tom A. Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, Anna M. Wu, Karin Welén
Format: Article
Publié: SpringerOpen 2020-02-01
Sujets:
Metastatic prostate cancer
Targeted alpha therapy
Alpha particles
Alpha-radioimmunotherapy
Astatine-211
Prostate stem cell antigen
Accès en ligne:https://doi.org/10.1186/s13550-020-0600-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doi.org/10.1186/s13550-020-0600-z

Documents similaires